Compare PBBK & SKYE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PBBK | SKYE |
|---|---|---|
| Founded | 1919 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 53.5M | 44.9M |
| IPO Year | N/A | N/A |
| Metric | PBBK | SKYE |
|---|---|---|
| Price | $22.78 | $1.00 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $14.75 |
| AVG Volume (30 Days) | 9.3K | ★ 249.9K |
| Earning Date | 10-23-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 53.39 | N/A |
| EPS | ★ 0.98 | N/A |
| Revenue | ★ $13,918,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $22.75 | ★ N/A |
| Revenue Growth | ★ 17.20 | N/A |
| 52 Week Low | $14.16 | $1.02 |
| 52 Week High | $22.92 | $5.75 |
| Indicator | PBBK | SKYE |
|---|---|---|
| Relative Strength Index (RSI) | 70.53 | 34.07 |
| Support Level | $21.40 | $1.04 |
| Resistance Level | $22.92 | $1.27 |
| Average True Range (ATR) | 0.43 | 0.10 |
| MACD | 0.05 | 0.01 |
| Stochastic Oscillator | 91.86 | 2.90 |
PB Bankshares Inc follows a community bank model and provides multiple services to individuals and small to midsize businesses. Its business consists of attracting retail and commercial deposits from the general public in its market area and investing those deposits, together with funds generated from operations and borrowings, in commercial real estate loans, commercial and industrial loans, construction, home equity lines of credit and to a lesser extent, one- to four-family residential real estate loans and consumer loans.
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.